Skip to main content
PMC home page
Journal of Medical Toxicology logoLink to Journal of Medical Toxicology
. 2008 Jun;4(2):132–140. doi: 10.1007/BF03160968

Case files of the New York City Poison Control Center: Antidotal strategies for the management of methotrexate toxicity

Silas W Smith 1,2,✉, Lewis S Nelson 1,2
PMCID: PMC3550133  PMID: 18570175

Full Text

The Full Text of this article is available as a PDF (409.2 KB).

Footnotes

No outside funding was received.

References

  • 1.Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin) N Engl J Med. 1948;238(23):787–793. doi: 10.1056/NEJM194806032382301. [DOI] [PubMed] [Google Scholar]
  • 2.Sacks MS, Bradford GT, Schoenbach EB. The response of acute leukemia to the administration of the folic acid antagonists, aminopterin and a-methopterin; report of 14 cases. Ann Intern Med. 1950;32(1):80–115. doi: 10.7326/0003-4819-32-1-80. [DOI] [PubMed] [Google Scholar]
  • 3.Farber S. Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer. Blood. 1949;4(2):160–167. [Google Scholar]
  • 4.Meyer LM, Miller FR, Rowen MJ, Bock G, Rutzky J. Treatment of acute leukemia with amethopterin (4-amino, 10-methyl pteroyl glutamic acid) Acta Haematol. 1950;4(3):157–167. doi: 10.1159/000203749. [DOI] [PubMed] [Google Scholar]
  • 5.Li MC, Hertz R, Spencer DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med. 1956;93(2):361–366. doi: 10.3181/00379727-93-22757. [DOI] [PubMed] [Google Scholar]
  • 6.Abel EA. Immunosuppressant and cytotoxic drugs: Unapproved uses or indications. Clin Dermatol. 2000;18(1)::95–101. doi: 10.1016/S0738-081X(99)00098-X. [DOI] [PubMed] [Google Scholar]
  • 7.Kawai S. Current drug therapy for rheumatoid arthritis. J Orthop Sci. 2003;8(2):259–263. doi: 10.1007/s007760300045. [DOI] [PubMed] [Google Scholar]
  • 8.Tanaka T, Hayashi H, Kutsuzawa T, Fujimoto S, Ichinoe K. Treatment of interstitial ectopic pregnancy with methotrexate: Report of a successful case. Fertil Steril. 1982;37(6):851–852. doi: 10.1016/s0015-0282(16)46349-1. [DOI] [PubMed] [Google Scholar]
  • 9.Lipscomb GH. Medical therapy for ectopic pregnancy. Semin Reprod Med. 2007;25(2):93–98. doi: 10.1055/s-2007-970048. [DOI] [PubMed] [Google Scholar]
  • 10.Christin-Maitre S, Bouchard P, Spitz IM. Medical termination of pregnancy. N Engl J Med. 2000;342(13):946–956. doi: 10.1056/NEJM200003303421307. [DOI] [PubMed] [Google Scholar]
  • 11.Remberger M, Ringden O. Similar outcome after unrelated allogeneic peripheral blood stem cell transplantation compared with bone marrow in children and adolescents. Transplantation. 2007;84(4):551–554. doi: 10.1097/01.tp.0000275184.41831.6d. [DOI] [PubMed] [Google Scholar]
  • 12.Srinivasan R, Takahashi Y, McCoy JP, et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol. 2006;133(3):305–314. doi: 10.1111/j.1365-2141.2006.06019.x. [DOI] [PubMed] [Google Scholar]
  • 13.Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer. 2004;100(10):2222–2232. doi: 10.1002/cncr.20255. [DOI] [PubMed] [Google Scholar]
  • 14.Bleyer WA. The clinical pharmacology of methotrexate: New applications of an old drug. Cancer. 1978;41(1):36–51. doi: 10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I. [DOI] [PubMed] [Google Scholar]
  • 15.Buchen S, Ngampolo D, Melton RG, et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer. 2005;92(3):480–487. doi: 10.1038/sj.bjc.6602337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med. 1986;314(8):471–477. doi: 10.1056/NEJM198602203140803. [DOI] [PubMed] [Google Scholar]
  • 17.Ruggiero A, Conter V, Milani M, et al. Intrathecal chemotherapy with antineoplastic agents in children. Paediatr Drugs. 2001;3(4):237–246. doi: 10.2165/00128072-200103040-00001. [DOI] [PubMed] [Google Scholar]
  • 18.Bleyer WA. Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from agerelated pharmacokinetics. Cancer Treat Rep. 1977;61(8):1419–1425. [PubMed] [Google Scholar]
  • 19.Roenigk HH, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: Consensus conference. J Am Acad Dermatol. 1998;38(3):478–485. doi: 10.1016/S0190-9622(98)70508-0. [DOI] [PubMed] [Google Scholar]
  • 20.Borchers AT, Keen CL, Cheema GS, Gershwin ME. The use of methotrexate in rheumatoid arthritis. Semin Arthritis Rheum. 2004;34(1):465–483. doi: 10.1016/j.semarthrit.2003.12.003. [DOI] [PubMed] [Google Scholar]
  • 21.Moisa A, Fritz P, Benz D, Wehner HD. Iatrogenically-related, fatal methotrexate intoxication: A series of four cases. Forensic Sci Int. 2006;156(2–3):154–157. doi: 10.1016/j.forsciint.2004.12.031. [DOI] [PubMed] [Google Scholar]
  • 22.Goldsmith P, Roach A. Methods to enhance the safety of methotrexate prescribing. J Clin Pharm Ther. 2007;32(4):327–331. doi: 10.1111/j.1365-2710.2007.00834.x. [DOI] [PubMed] [Google Scholar]
  • 23.Dervieux T, Furst D, Lein DO, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004;50(9):2766–2774. doi: 10.1002/art.20460. [DOI] [PubMed] [Google Scholar]
  • 24.Genestier L, Paillot R, Quemeneur L, Izeradjene K, Revillard JP. Mechanisms of action of methotrexate. Immunopharmacology. 2000;47(2–3):247–257. doi: 10.1016/S0162-3109(00)00189-2. [DOI] [PubMed] [Google Scholar]
  • 25.Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem. 1996;42(8):1322–1329. [PubMed] [Google Scholar]
  • 26.Joerger M, Huitema AD, van den Bongard HJ, et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol. 2006;62(1):71–80. doi: 10.1111/j.1365-2125.2005.02513.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Comandone A, Passera R, Boglione A, Tagini V, Ferrari S, Cattel L. High dose methotrexate in adult patients with osteosarcoma: Clinical and pharmacokinetic results. Acta Oncol. 2005;44(4):406–411. doi: 10.1080/02841860510029770. [DOI] [PubMed] [Google Scholar]
  • 28.Bore P, Bruno R, Lena N, Favre R, Cano JP. Methotrexate and 7-hydroxy-methotrexate pharmacokinetics following intravenous bolus administration and high-dose infusion of methotrexate. Eur J Cancer Clin Oncol. 1987;23(9):1385–1390. doi: 10.1016/0277-5379(87)90124-6. [DOI] [PubMed] [Google Scholar]
  • 29.Thompson PA, Murry DJ, Rosner GL, et al. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2007;59(6):847–853. doi: 10.1007/s00280-006-0388-1. [DOI] [PubMed] [Google Scholar]
  • 30.Skärby T, Jönsson P, Hjorth L, et al. High-dose methotrexate: On the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL) Cancer Chemother Pharmacol. 2003;51(4):311–320. doi: 10.1007/s00280-002-0552-1. [DOI] [PubMed] [Google Scholar]
  • 31.Bostrom BC, Erdmann GR, Kamen BA. Systemic methotrexate exposure is greater after intrathecal than after oral administration. J Pediatr Hematol Oncol. 2003;25(2):114–117. doi: 10.1097/00043426-200302000-00006. [DOI] [PubMed] [Google Scholar]
  • 32.Hartman SC, Buchanan JM. Biosynthesis of the purines. XXVI. The identification of the formyl donors of the transformylation reactions. J Biol Chem. 1959;234(7):1812–1816. [PubMed] [Google Scholar]
  • 33.Anguera MC, Suh JR, Ghandour H, Nasrallah IM, Selhub J, Stover PJ. Methenyltetrahydrofolate synthetase regulates folate turnover and accumulation. J Biol Chem. 2003;278(32):29856–29862. doi: 10.1074/jbc.M302883200. [DOI] [PubMed] [Google Scholar]
  • 34.Lingg RM, Hempel G, Rots MG, Van Zantwijk CH, Boos J, Kaspers GJ. Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay. Cancer Chemother Pharmacol. 2005;56(3):322–327. doi: 10.1007/s00280-005-1032-1. [DOI] [PubMed] [Google Scholar]
  • 35.Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem. 1985;260(17):9720–9726. [PubMed] [Google Scholar]
  • 36.Uga H, Kuramori C, Ohta A, et al. A new mechanism of methotrexate action revealed by target screening with affinity beads. Mol Pharmacol. 2006;70(5):1832–1839. doi: 10.1124/mol.106.025866. [DOI] [PubMed] [Google Scholar]
  • 37.Harned TM, Mascarenhas L. Severe methotrexate toxicity precipitated by intravenous radiographic contrast. J Pediatr Hematol Oncol. 2007;29(7):496–499. doi: 10.1097/MPH.0b013e3180683c04. [DOI] [PubMed] [Google Scholar]
  • 38.Weisman MH, Furst DE, Park GS, et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum. 2006;54(2):607–612. doi: 10.1002/art.21573. [DOI] [PubMed] [Google Scholar]
  • 39.Jahnke K, Korfel A, Martus P, et al. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol. 2005;16(3):445–449. doi: 10.1093/annonc/mdi075. [DOI] [PubMed] [Google Scholar]
  • 40.Cannon GW. Methotrexate pulmonary toxicity. Rheum Dis Clin North Am. 1997;23(4):917–937. doi: 10.1016/S0889-857X(05)70366-5. [DOI] [PubMed] [Google Scholar]
  • 41.Erasmus JJ, McAdams HP, Rossi SE. Drug-induced lung injury. Semin Roentgenol. 2002;37(1):72–81. doi: 10.1053/sroe.2002.0000. [DOI] [PubMed] [Google Scholar]
  • 42.Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997;127(5):356–364. doi: 10.7326/0003-4819-127-5-199709010-00003. [DOI] [PubMed] [Google Scholar]
  • 43.Shapiro CL, Yeap BY, Godleski J, et al. Drug-related pulmonary toxicity in non-Hodgkin’s lymphoma. Comparative results with three different treatment regimens. Cancer. 1991;68(4):699–705. doi: 10.1002/1097-0142(19910815)68:4<699::AID-CNCR2820680406>3.0.CO;2-5. [DOI] [PubMed] [Google Scholar]
  • 44.Vezmar S, Becker A, Bode U, Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy. 2003;49(1–2):92–104. doi: 10.1159/000069773. [DOI] [PubMed] [Google Scholar]
  • 45.Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used antineoplastic agents (first of two parts) N Engl J Med. 1974;291(2):75–81. doi: 10.1056/NEJM197407112910205. [DOI] [PubMed] [Google Scholar]
  • 46.Norrell H, Wilson CB, Slagel DE, Clark DB. Leukoencephalopathy following the administration of methotrexate into the cerebrospinal fluid in the treatment of primary brain tumors. Cancer. 1974;33(4):923–932. doi: 10.1002/1097-0142(197404)33:4<923::AID-CNCR2820330406>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
  • 47.Rubinstein LJ, Herman MM, Long TF, Wilbur JR. Disseminated necrotizing leukoencephalopathy: A complication of treated central nervous system leukemia and lymphoma. Cancer. 1975;35(2):291–305. doi: 10.1002/1097-0142(197502)35:2<291::AID-CNCR2820350202>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
  • 48.Fotoohi K, Skärby T, Söderhäll S, Peterson C, Albertioni F. Interference of 7-hydroxymethotrexate with the determination of methotrexate in plasma samples from children with acute lymphoblastic leukemia employing routine clinical assays. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;817(2):139–144. doi: 10.1016/j.jchromb.2004.11.037. [DOI] [PubMed] [Google Scholar]
  • 49.Nirenberg A, Mosende C, Mehta BM, Gisolfi AL, Rosen G. High-dose methotrexate with citrovorum factor rescue: Predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treat Rep. 1977;61(5):779–783. [PubMed] [Google Scholar]
  • 50.Proudfoot AT, Krenzelok EP, Vale JA. Position paper on urine alkalinization. J Toxicol Clin Toxicol. 2004;42(1):1–26. doi: 10.1081/CLT-120028740. [DOI] [PubMed] [Google Scholar]
  • 51.Sasaki K, Tanaka J, Fujimoto T. Theoretically required urinary flow during high-dose methotrexate infusion. Cancer Chemother Pharmacol. 1984;13(1):9–13. doi: 10.1007/BF00401438. [DOI] [PubMed] [Google Scholar]
  • 52.Sand TE, Jacobsen S. Effect of urine pH and flow on renal clearance of methotrexate. Eur J Clin Pharmacol. 1981;19(6):453–456. doi: 10.1007/BF00548590. [DOI] [PubMed] [Google Scholar]
  • 53.Christensen ML, Rivera GK, Crom WR, Hancock ML, Evans WE. Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia. J Clin Oncol. 1988;6(5):797–801. doi: 10.1200/JCO.1988.6.5.797. [DOI] [PubMed] [Google Scholar]
  • 54.Sauberlich HE, Baumann CA. A factor required for the growth of Leuconostoc citrovorum. J Biol Chem. 1948;176(1):165–173. [PubMed] [Google Scholar]
  • 55.Schoenbach EB, Greenspan EM, Colsky J. Reversal of aminopterin and amethopterin toxicity by citrovorum factor. J Am Med Assoc. 1950;144(18):1558–1560. doi: 10.1001/jama.1950.62920180002006a. [DOI] [PubMed] [Google Scholar]
  • 56.Jaffe N, Jorgensen K, Robertson R, George M, Letvak L, Barrett G. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma. Anticancer Drugs. 1993;4(5):559–564. doi: 10.1097/00001813-199310000-00005. [DOI] [PubMed] [Google Scholar]
  • 57.Bleyer WA. New vistas for leucovorin in cancer chemotherapy. Cancer. 1989;63(6):995–1007. doi: 10.1002/1097-0142(19890315)63:6+<995::AID-CNCR2820631302>3.0.CO;2-R. [DOI] [PubMed] [Google Scholar]
  • 58.Schilsky RL, Ratain MJ. Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. J Natl Cancer Inst. 1990;82(17):1411–1415. doi: 10.1093/jnci/82.17.1411. [DOI] [PubMed] [Google Scholar]
  • 59.Bleyer WA. Methotrexate: Clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev. 1977;4(2):87–101. doi: 10.1016/S0305-7372(77)80007-8. [DOI] [PubMed] [Google Scholar]
  • 60.Flombaum CD, Meyers PA. High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol. 1999;17(5):1589–1594. doi: 10.1200/JCO.1999.17.5.1589. [DOI] [PubMed] [Google Scholar]
  • 61.Pinedo HM, Zaharko DS, Bull JM, Chabner BA. The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res. 1976;36(12):4418–4424. [PubMed] [Google Scholar]
  • 62.Jardine LF, Ingram LC, Bleyer WA. Intrathecal leucovorin after intrathecal methotrexate overdose. J Pediatr Hematol Oncol. 1996;18(3):302–304. doi: 10.1097/00043426-199608000-00014. [DOI] [PubMed] [Google Scholar]
  • 63.Trinkle R, Wu JK. Intrathecal leukovorin after intrathecal methotrexate overdose. J Pediatr Hematol Oncol. 1997;19(3):267–269. doi: 10.1097/00043426-199705000-00019. [DOI] [PubMed] [Google Scholar]
  • 64.Grem JL, King SA, Sorensen JM, Christian MC. Clinical use of thymidine as a rescue agent from methotrexate toxicity. Invest New Drugs. 1991;9(3):281–290. doi: 10.1007/BF00176985. [DOI] [PubMed] [Google Scholar]
  • 65.Graham-Cole CL, Thomas HD, Taylor GA, et al. An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed. Cancer Chemother Pharmacol. 2007;59(2):197–206. doi: 10.1007/s00280-006-0258-x. [DOI] [PubMed] [Google Scholar]
  • 66.Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694–703. doi: 10.1634/theoncologist.11-6-694. [DOI] [PubMed] [Google Scholar]
  • 67.Howell SB, Ensminger WD, Krishan A, Frei E. Thymidine rescue of high-dose methotrexate in humans. Cancer Res. 1978;38(2):325–330. [PubMed] [Google Scholar]
  • 68.Rowsell S, Pauptit RA, Tucker AD, Melton RG, Blow DM, Brick P. Crystal structure of carboxypeptidase G2, a bacterial enzyme with applications in cancer therapy. Structure. 1997;5(3):337–347. doi: 10.1016/S0969-2126(97)00191-3. [DOI] [PubMed] [Google Scholar]
  • 69.Albrecht AM, Boldizsar E, Hutchison DJ. Carboxypeptidase displaying differential velocity in hydrolysis of methotrexate, 5-methyltetrahydrofolic acid, and leucovorin. J Bacteriol. 1978;134(2):506–513. doi: 10.1128/jb.134.2.506-513.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Sherwood RF, Melton RG, Alwan SM, Hughes P. Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method. Eur J Biochem. 1985;148(3):447–453. doi: 10.1111/j.1432-1033.1985.tb08860.x. [DOI] [PubMed] [Google Scholar]
  • 71.Widemann BC, Balis FM, Shalabi A, et al. Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst. 2004;96(20):1557–1559. doi: 10.1093/jnci/djh270. [DOI] [PubMed] [Google Scholar]
  • 72.O’Marcaigh AS, Johnson CM, Smithson WA, et al. Successful treatment of intrathecal methotrexate overdose by using ventriculolumbar perfusion and intrathecal instillation of carboxypeptidase G2. Mayo Clin Proc. 1996;71(2):161–165. doi: 10.4065/71.2.161. [DOI] [PubMed] [Google Scholar]
  • 73.Saland JM, Leavey PJ, Bash RO, Hansch E, Arbus GS. Quigley R. Effective removal of methotrexate by high-flux hemodialysis. Pediatr Nephrol. 2002;17(10):825–829. doi: 10.1007/s00467-002-0946-7. [DOI] [PubMed] [Google Scholar]
  • 74.Wall SM, Johansen MJ, Molony DA, DuBose TD, Jaffe N, Madden T. Effective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis. 1996;28(6):846–854. doi: 10.1016/S0272-6386(96)90384-4. [DOI] [PubMed] [Google Scholar]
  • 75.Relling MV, Stapleton FB, Ochs J, et al. Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion. Cancer. 1988;62(5):884–888. doi: 10.1002/1097-0142(19880901)62:5<884::AID-CNCR2820620506>3.0.CO;2-A. [DOI] [PubMed] [Google Scholar]
  • 76.Molina R, Fabian C, Cowley B. Use of charcoal hemoperfusion with sequential hemodialysis to reduce serum methotrexate levels in a patient with acute renal insufficiency. Am J Med. 1987;82(2):350–352. doi: 10.1016/0002-9343(87)90085-4. [DOI] [PubMed] [Google Scholar]
  • 77.Djerassi I, Ciesielka W, Kim JS. Removal of methotrexate by filtration-adsorption using charcoal filters or by hemodialysis. Cancer Treat Rep. 1977;61(4):751–752. [PubMed] [Google Scholar]
  • 78.Ahmad S, Shen FH, Bleyer WA. Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis. Arch Intern Med. 1978;138(7):1146–1147. doi: 10.1001/archinte.138.7.1146. [DOI] [PubMed] [Google Scholar]
  • 79.Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB. Removal of methotrexate by peritoneal dialysis and hemodialysis in a single patient with end-stage renal disease. Am J Med Sci. 2006;332(3):156–158. doi: 10.1097/00000441-200609000-00013. [DOI] [PubMed] [Google Scholar]
  • 80.Toone JR, Applegarth DA, Coulter-Mackie MB, James ER. Recurrent mutations in P- and T-proteins of the glycine cleavage complex and a novel T-protein mutation (N145I): a strategy for the molecular investigation of patients with nonketotic hyperglycinemia (NKH) Mol Genet Metab. 2001;72(4):322–325. doi: 10.1006/mgme.2001.3158. [DOI] [PubMed] [Google Scholar]
  • 81.Anguera MC, Suh JR, Ghandour H, Nasrallah IM, Selhub J, Stover PJ. Methenyltetrahydrofolate synthetase regulates folate turnover and accumulation. J Biol Chem. 2003;278(32):29856–29862. doi: 10.1074/jbc.M302883200. [DOI] [PubMed] [Google Scholar]
  • 82.Silverman M, Keresztesy JC, Koval GJ, Gardiner RC. Citrovorum factor and the synthesis of formylglutamic acid. J Biol Chem. 1957;226(1):83–94. [PubMed] [Google Scholar]

Articles from Journal of Medical Toxicology are provided here courtesy of Springer

RESOURCES